Medicamen Biotech posted solid consolidated revenue growth of 21.66% to Rs 197.77 crore in FY 2025-26. While the firm successfully expanded its oncology and CDMO footprint, the annual report reveals several regulatory and governance lapses, including CSR shortfalls and committee composition issues. The company has declared a final dividend of Rs 1 per share, with the AGM scheduled for September 26, 2026.
Medicamen Biotech FY26: Revenue Growth Meets Compliance Hurdles
Consolidated revenue climbed 21.66% to Rs 197.77 crore; Profit After Tax rose 49.43% to Rs 9.80 crore.
Reader Takeaway: Strong topline growth in oncology and CDMO segments is offset by recurring compliance and governance process failures.
What just happened
Medicamen Biotech released its FY 2025-26 Annual Report, confirming its 33rd Annual General Meeting (AGM) for September 26, 2026. Shareholders will receive a final dividend of Rs 1 per equity share (10%), with the record date set for September 19, 2026. The report showcases robust operational performance alongside a series of candid disclosures regarding internal governance and regulatory compliance.
Why this matters
The company demonstrated clear momentum in its high-margin segments, particularly through its subsidiary Medicamen Lifesciences, which recorded 71% year-on-year sales growth. Expansion into international markets like Denmark and Norway, coupled with successful CDMO projects for a US-based client, indicates strong product viability. However, investors must weigh this growth against identified governance gaps that could pose long-term reputational or financial risks if not rectified.
Governance and Regulatory Observations
The Secretarial Auditor flagged several compliance discrepancies:
- Regulatory Penalties: The company paid fines totaling Rs 1,18,000 to the NSE and BSE for delays in shareholding filings and non-compliant composition of the Nomination and Remuneration Committee.
- Related Party Transactions: Transactions with Shivalik Rasayan Limited exceeded the authorized omnibus limit by Rs 1.95 crore.
- CSR and POSH: A CSR spending shortfall occurred due to calculation errors, and the company failed to submit the required POSH Act annual report for 2025.
What to track next
Investors should monitor management’s remedial actions regarding the identified CSR shortfall and the strengthening of the internal compliance framework. The board's ability to ensure accurate reporting and committee oversight in upcoming quarters will be a critical metric for evaluating operational quality alongside financial performance.